Gliatech
This article was originally published in The Gray Sheet
Executive Summary
Health Policy Associates hired as independent auditor to assist firm in responding to FDA's Application Integrity Policy (AIP) letter questioning post-market data for the Adcon-L gel anti-adhesion product for lumbar surgery. FDA recently suspended review of one premarket approval application and two PMA supplements submitted by the firm (1"The Gray Sheet" Jan. 1, 2001, p. 5)You may also be interested in...
Adcon Data Will Be Evaluated By Third Party In Wake Of FDA Action - Gliatech
Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
UK Set For January Brexit After Conservatives Win Election
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: